Emyria Ltd (ASX:EMD) Michael Winlo tells Proactive the company has been accepted into the US National Institute of Health’s (NIH) Preclinical Screening Platform for Pain program. The NIH’s National Institute of Neurological Disorders and Stroke (NINDS) � also the leading funder of neurological research in the US will run the study as part of a broader initiative to stem the opioid public health crisis.
Hashtag: #Emyria
The issuer is solely responsible for the content of this announcement.
BANGKOK, THAILAND - Media OutReach Newswire - 22 November 2024 - PT. Eka Mas Republik,…
HONG KONG SAR - Media OutReach Newswire - 21 November 2024 - UOB Art Academy…
HONG KONG SAR - Media OutReach Newswire - 21 November 202 - Aomori Crafts from…
Collect FunStamps on the New 7-Eleven App and Redeem for FREE HONG KONG SAR -…
Their project, SilentGuide, is a pair of smart glasses that transcribes spoken words into subtitles,…
Whimsical White Christmas KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 21 November 2024 –…